Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia.
For research use only. We do not sell to patients.
- CAS No.: 137-58-6
- Formula: C14H22N2O
- Molecular Weight:234.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All MEK Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
>500 μM
Compound: lidocaine
|
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
|
[PMID: 23241029] |
| HEK293 | IC50 |
180 μM
Compound: 1
|
Inhibition of human TREK-1 expressed in HEK293 cells by patch-clamp technique
Inhibition of human TREK-1 expressed in HEK293 cells by patch-clamp technique
|
[PMID: 23121096] |
| HEK293 | IC50 |
207 μM
Compound: 35
|
Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents
Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents
|
[PMID: 26588045] |
Lidocaine GMP (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation[2].
Lidocaine GMP (1-10 nM; 24-72 h) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours[2].
Lidocaine GMP (10 nM; 48 h) increases significantly the apoptotic cell rate[2].
Lidocaine GMP (10 nM; 48 h) down-regulates Cyclin D1 and up-regulates p21 expression significantly[2].
Lidocaine (100 μM, 200 μM, 28 d) slowed down the conduction velocity (CV) in hPSC lines[4].
Lidocaine (0.1-2000 μM, 5 min) exhibits limited use-dependent block (UDB) in hiPSC-derived cardiomyocytes[5].
Lidocaine (30 μM) reduces QT interval of LQTS-CMs to a normal level[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 137-58-6
-
Molecular Weight 234.34
-
Formula C14H22N2O
-
SMILES
O=C(NC1=C(C)C=CC=C1C)CN(CC)CC
-
Synonyms
Lignocaine (GMP)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11. [Content Brief]
[2]. Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. [Content Brief]
[3]. Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6. [Content Brief]
[4]. Kadota S, et al. Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. Eur Heart J. 2013 Apr;34(15):1147-56. [Content Brief]
[5]. Potet F, et al. GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Mol Pharmacol. 2020 Nov;98(5):540-547. [Content Brief]
[6]. Wang F, et al. In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment. Cells. 2022 Aug 11;11(16):2495. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lidocaine (GMP) Related Classifications
HY-B0185G Related Classifications
Powered by Bioz